{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:45:18Z","timestamp":1782539118260,"version":"3.54.5"},"reference-count":35,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Background:<\/jats:bold>\n Omalizumab is a well-established add-on therapy for patients with moderate-to-severe asthma. However, there is limited systematic evidence on the long-term outcomes after discontinuation of this treatment.\n Objective:<\/jats:bold>\n To address this evidence\n gap, this review aimed to systematically evaluate the follow-up outcomes in patients with moderate-to-severe asthma after discontinuation of omalizumab treatment.\n Methods:<\/jats:bold>\n The research was conducted in accordance with the systematic reviews and meta-analyses guidelines.\n We systematically searched medical literature data bases from December 2003 to August 2025 for observational studies (prospective or retrospective) on omalizumab discontinuation in moderate-to-severe asthma. Data extraction was conducted on key variables: omalizumab treatment regimens, postdiscontinuation\n long-term outcomes, asthma control status, relapse risk factors, asthma exacerbation rates, corticosteroid use, and patterns of omalizumab reinitiation.\n Results:<\/jats:bold>\n A total of 11 eligible studies were included in the review. After discontinuation, most patients showed no remarkable\n changes in forced expiratory volume in 1 second, fractional exhaled nitric oxide level, total immunoglobulin E value, or absolute eosinophil count. Moreover, no obvious deterioration was observed in patient-reported quality of life. These findings confirm the sustained long-term benefits of\n previous omalizumab add-on therapy because the majority of patients maintained favorable disease control after discontinuation. Subgroup analyses further indicated that asthma exacerbations, when they occurred, predominantly occurred within the first year after discontinuation.\n Conclusion:<\/jats:bold>\n This review indicates that, although most patients maintain stable objective indicators after omalizumab discontinuation, a significant proportion are at increased risk for exacerbations, deterioration in asthma control, and increased corticosteroid use, particularly within the first year.\n <\/jats:p>","DOI":"10.2500\/aap.2026.47.260016","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:42:02Z","timestamp":1777437722000},"page":"e24-e35","source":"Crossref","is-referenced-by-count":1,"title":["Follow-up after discontinuation of omalizumab in patients with moderate-to-severe asthma: A systematic review"],"prefix":"10.2500","volume":"47","author":[{"given":"Qiu-Li","family":"Yan","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics and Clinical Allergy Center, Suzhou Wujiang District Children's Hospital, Wujiang Branch of Children's Hospital of Soochow University, Suzhou, China and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Allergology and Clinical Allergy Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Si","family":"Niu","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics and Clinical Allergy Center, Suzhou Wujiang District Children's Hospital, Wujiang Branch of Children's Hospital of Soochow University, Suzhou, China and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Jin","family":"Shi","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics and Clinical Allergy Center, Suzhou Wujiang District Children's Hospital, Wujiang Branch of Children's Hospital of Soochow University, Suzhou, China and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics and Clinical Allergy Center, Suzhou Wujiang District Children's Hospital, Wujiang Branch of Children's Hospital of Soochow University, Suzhou, China and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics and Clinical Allergy Center, Suzhou Wujiang District Children's Hospital, Wujiang Branch of Children's Hospital of Soochow University, Suzhou, China and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Allergology and Clinical Allergy Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors","volume":"42","author":"Stern","year":"2020","journal-title":"Semin Immunopathol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(19)31147-X","article-title":"Prevalence, risk factors, and management of asthma in China: a national cross-sectional study","volume":"394","author":"Huang","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/ped.2018.0886","article-title":"Asthma endotyping and biomarkers in childhood asthma","volume":"31","author":"Licari","year":"2018","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"B4","first-page":"341","article-title":"Chinese expert consensus on the use of omalizumab in allergic asthma (2021 version)","volume":"45","year":"2022","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B5","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1033511","DOI":"10.3389\/fped.2022.1033511","article-title":"Severe pediatric asthma therapy: omalizumab-a systematic review and meta-analysis of efficacy and safety profile","volume":"10","author":"Fenu","year":"2023","journal-title":"Front Pediatr"},{"key":"B7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ppul.26764","article-title":"Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: a population-based cohort study","volume":"59","author":"Monzio Compagnoni","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/1744666X.2019.1574571","article-title":"Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018","volume":"15","author":"MacDonald","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1159\/000525723","article-title":"Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level be used as a biological marker to decide discontinuing omalizumab treatment?","volume":"183","author":"Arslan","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/ppul.26500","article-title":"Prospective follow up after omalizumab discontinuation in a cohort of children with severe asthma","volume":"58","author":"Ferraro","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.clinthera.2018.09.004","article-title":"Small, prospective, observational, pilot study in patients with severe asthma after discontinuation of omalizumab treatment","volume":"40","author":"Kr\u010dmov\u00e1","year":"2018","journal-title":"Clin Ther"},{"key":"B14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/thoraxjnl-2017-210017","article-title":"Duration of the efficacy of omalizumab after treatment discontinuation in \u2018real life\u2019 severe asthma","volume":"73","author":"Vennera","year":"2018","journal-title":"Thorax"},{"key":"B15","first-page":"1","article-title":"Loss of asthma control after cessation of omalizumab treatment: real life data","volume":"31","author":"Kupry\u015b-Lipi\u0144ska","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/ACI.0000000000000161","article-title":"Four-year follow-up in children with moderate\/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment","volume":"15","author":"Baena-Cagnani","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2014.02.003","article-title":"Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control","volume":"108","author":"Molimard","year":"2014","journal-title":"Respir Med"},{"issue":"Suppl. 1","key":"B18","doi-asserted-by":"crossref","first-page":"A75","DOI":"10.1186\/1939-4551-8-S1-A75","article-title":"Follow-up of asthma control and quality of life after discontinuation of omalizumab in severe asthmatic patients","volume":"8","author":"Nayci","year":"2015","journal-title":"World Allergy Organ J"},{"key":"B19","first-page":"108","article-title":"Omalizumab in severe asthma: evaluation of the clinical impact after its withdrawal","volume":"23","author":"de Sousa","year":"2017","journal-title":"Rev Port Pneumol (2006)"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1529624","DOI":"10.3389\/falgy.2025.1529624","article-title":"Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma","volume":"6","author":"Foti Randazzese","year":"2025","journal-title":"Front Allergy"},{"key":"B21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.resinv.2024.06.005","article-title":"Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: a real-world clinical practice","volume":"62","author":"Hamada","year":"2024","journal-title":"Respir Investig"},{"key":"B22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/JAA.S406628","article-title":"Real-world safety and effectiveness of omalizumab in moderate to severe allergic asthma patients in China: a post-authorization study","volume":"16","author":"Su","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2147\/JAA.S410592","article-title":"Effect of biologic therapies on airway hyperresponsiveness and allergic response: a systematic literature review","volume":"16","author":"Spahn","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"B25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"e001549","DOI":"10.1136\/bmjresp-2022-001549","article-title":"Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study","volume":"10","author":"Wang","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"B27","doi-asserted-by":"crossref","first-page":"17534666231221771","DOI":"10.1177\/17534666231221771","article-title":"Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"B28","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3390\/ijms25053056","article-title":"The incredible adventure of omalizumab","volume":"25","author":"Domingo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13601-017-0143-1","article-title":"Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months","volume":"7","author":"Riccio","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"B30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: targeting IgE, cytokine, and alarmin pathways","volume":"328","author":"Eggel","year":"2024","journal-title":"Immunol Rev"},{"issue":"Suppl. 2","key":"B31","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/j.jaci.2008.12.571","article-title":"Omalizumab (Xolair) may normalize IgE production rate in patients with moderate-to-severe atopic asthma","volume":"123","author":"Lowe","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1398-9995.2009.02144.x","article-title":"After 6 years with Xolair; a 3-year withdrawal follow-up","volume":"65","author":"Nopp","year":"2010","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/all.13678","article-title":"Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study","volume":"74","author":"Deschildre","year":"2019","journal-title":"Allergy"},{"key":"B35","doi-asserted-by":"crossref","first-page":"2103130","DOI":"10.1183\/13993003.03130-2021","article-title":"Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients","volume":"60","author":"Humbert","year":"2022","journal-title":"Eur Respir J"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000003\/art00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:46:08Z","timestamp":1782535568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["1088-5412(20260501)47:3L.24;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260016","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}